The CDMO will develop and produce an AAV5 vector for MQ-201, an RNAi therapy moving toward its first clinical trial.
Nov. 20, 2026
The 120,000-liter facility in South Korea reached GMP readiness six months ahead of schedule, with commercial production planned for 2027.
Nov. 19, 2026
The CDMO will develop the antibody component of the ADC developer’s lead candidate and manufacture GMP material for a planned Phase 1 trial.
Nov. 19, 2026
The agreement covers drug substance and drug product manufacturing, with commercial production targeted to begin in 2027 at the CDMO’s Songdo facility.
Nov. 18, 2026
The partnership will establish East Coast manufacturing capacity for the cell therapy and support a planned expansion of Made Scientific’s Princeton campus.
Nov. 18, 2026
Three biopharma developers, including the Institute of Science Tokyo, selected the CDMO’s Yokohama site for cell therapy process development and manufacturing support.
Nov. 17, 2026
The agreement gives the Hong Kong-based pharmaceutical company exclusive rights to use the TfR1 platform in up to two neurodegenerative disease programs.
Nov. 17, 2026
The acquisition of the Chemistry, Manufacturing and Controls team adds more than 35 specialists in biologics development, production oversight, and regulatory strategy.
Nov. 16, 2026

Looking for Something?